MARKET

CRVS

CRVS

Corvus Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.550
+0.240
+5.57%
After Hours: 4.550 0 0.00% 16:00 02/20 EST
OPEN
4.270
PREV CLOSE
4.310
HIGH
4.620
LOW
4.130
VOLUME
160.30K
TURNOVER
--
52 WEEK HIGH
8.10
52 WEEK LOW
2.530
MARKET CAP
132.78M
P/E (TTM)
-2.8924
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of CRVS and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 4 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

CRVS News

  • Richard Miller Awarded 2020 Drug Hunter Award by UC Drug Discovery Consortium
  • GlobeNewswire.1d ago
  • Corvus Pharma Highlights Presentation Of Clinical Data From Phase 1b/2 Trial Of Ciforadenant At American Society of Clinical Oncology's Genitourinary Cancers Symposium
  • Benzinga.02/13 13:08
  • Corvus Pharmaceuticals Presents Updated Clinical Data from its Phase 1b/2 Clinical Trial of Ciforadenant at the 2020 American Society of Clinical Oncologys Genitourinary Cancers Symposium
  • GlobeNewswire.02/13 13:00
  • The Week Ahead In Biotech: SMID-Cap Earnings In The Spotlight
  • Benzinga.02/09 20:22

More

Industry

Biotechnology & Medical Research
+0.09%
Pharmaceuticals & Medical Research
-0.40%

Hot Stocks

Name
Price
%Change

About CRVS

Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology therapies. The Company is developing drugs and antibodies that block crucial immune checkpoints and reprogram immune T-cells. The Company has a pipeline of four immuno-oncology programs, three of which focus on the adenosine-cancer axis to modulate an immune response. The Company's lead product candidate, CPI-444, is an oral, small molecule antagonist of the A2A receptor for adenosine, an immune checkpoint. Its other products include adenosine production inhibitor (a monoclonal anti-CD73 antibody); adenosine A2B antagonist, and interleukin-2 (IL-2)-inducible T cell kinase (ITK) inhibitors. As of September 30, 2016, the Company had not generated any revenue.
More

Webull offers Corvus Pharmaceuticals Inc (CRVS) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.